AZ AZN AstraZeneca PLC Loading... : Bullish and Bearish Analyst Opinions

AstraZeneca announces Breztri is now available in the US as the first and only fixed-dose triple therapy for asthma patients aged 12 and older.

AstraZeneca highlights rare diseases as a key growth driver in its push to reach 80 billion dollars in revenue according to the Financial Times.

Morgan Stanley lowers AstraZeneca valuation and reduces its target price to 15,300 pence.

AstraZeneca agrees to pay Dizal Jiangsu Pharmaceutical 600 million dollars upfront for global rights to a lung cancer drug.

Pre-market movers include AZN falling on trial failure, COST and PEP down on consumer weakness, LEVI on weak outlook, CBRS up on AI expansion, IBM and MSFT down on Starbucks AI development, ENVX and AZZ up on news, FCEL on Siemens deal, CRM downgraded, and PSKY downgraded to sell.

AstraZeneca shares fall after its drug Wainua failed to reduce deaths in a heart condition trial.

AstraZeneca shares are set for their biggest one-day decline since March 2020 according to the reported headline.

AstraZeneca shares fall 9 percent after its drug Wainua fails to prevent heart problems in clinical trial results.

Reports a $1.9B respiratory drug licensing deal; fundamental development, no directional view.

AstraZeneca PLC announced that the European Union has approved Enhertu for HER2-positive solid tumour indications.

AstraZeneca PLC announced that its drug Datroway has been recommended for European Union approval in the treatment of triple-negative breast cancer.

AstraZeneca reports positive outcomes in the Mulberry Phase III trial for ALXN1850, demonstrating a favourable safety profile and achieving a key secondary endpoint in bone health.

The author notes that most large pharma companies have seen minimal M&A activity over the last 24 months while Eli Lilly remains aggressive, providing a factual observation rather than a trade call.

The author presents a factual analysis of M&A activity in the biotech sector since Covid, noting that many large pharma companies have not yet engaged in significant deals, but does not express a personal position or forward-looking trade call.

AstraZeneca announces that Ultomiris has been accepted for priority review in the U.S. for treating immunoglobulin A nephropathy in adults.

The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.

European stock movers show SoftwareOne up 5.3 percent and Givaudan up 2.8 percent while AstraZeneca and GSK each fall 1.3 percent.

AstraZeneca's experimental obesity pill achieved up to 11.8% weight loss in a mid-stage trial as the company advances into the weight-loss drug market.

Reports a warning from AstraZeneca's chief about potential drug withholding in Europe, no directional view stated.

AstraZeneca reports that Ultomiris achieved a 43.4 percent reduction in proteinuria versus placebo in adults with IgA nephropathy at 34 weeks in a Phase 3 trial.

AstraZeneca on track for $80B

Author provides a detailed valuation analysis for ABVX with a 105% premium price target of ~$218, implying a bullish acquisition thesis based on comps and peak sales multiples.

The author presents a historical case study of CinCor Pharma and AstraZeneca's acquisition dynamics as an educational lesson, not a current trade idea.

The author urges AZN to "bring it home," expressing a bullish forward-looking view on the stock.

Adam May replies to Benjo McKazuie by simply listing the tickers $AZN, $LLY, and $SNY without any directional opinion or market context.

Reeves explicitly states they have "secured a deal around pharmaceuticals" with the US which is "crucial for the UK" and asserts these terms are "not affected by the Supreme Court ruling" or current diplomatic tensions. While the broader UK-US trade relationship faces headwinds due to the UK's refusal to join offensive military action against Iran, the pharmaceutical sector has been ring-fenced. This regulatory certainty provides a safe harbor for UK pharma giants compared to other export sectors that may face retaliatory tariffs or "uncertainty." Long UK Pharma majors as a defensive play against geopolitical volatility; they retain access to their most critical market (US) regardless of the political spat. Unexpected executive orders from the US administration specifically targeting UK imports despite prior agreements.

Berkshire Hathaway bought shares in The New York Times, AstraZeneca, and Occidental Petroleum. This represents a classic defensive rotation: Media (subscription stability), Healthcare (drug demand independent of economy), and Energy (inflation hedge). LONG NYT, AZN, OXY. Sector-specific regulatory risks (drug pricing for AZN, oil prices for OXY).

13F filings reveal Berkshire Hathaway has been "buying into AstraZeneca" while simultaneously slashing stakes in major US tech and financials. When the "Oracle of Omaha" rotates out of cyclical consumer/tech names into defensive healthcare, it signals a shift toward safety and undervaluation in the pharma sector. LONG AZN as a copy-trade of Berkshire's defensive rotation. Drug pipeline failures or regulatory pricing pressure in the pharmaceutical sector.

The price target increase from Berenberg indicates a professional analyst's view of further upside for the stock.

The market is panic-selling companies perceived as "AI Disruptable" (Software, Services). Investors should seek "Non-AI Risk Trades"—companies with hard assets or complex pipelines that AI cannot easily replicate. Caterpillar (Heavy Machinery) and AstraZeneca (Pharma Pipeline) represent physical/complex value that is safe from the "AI Scare" narrative. Buy high-quality "Real World" companies as a defensive play against the AI disruption narrative. Global economic slowdown hurting industrials (CAT) or drug trial failures (AZN).